Buforin IIb and bilirubin co-loaded CeO₂ nanoparticles boost 7-day survival to 60% and mitigate sepsis-related encephalopathy

Sepsis, a dysregulated host response to infection, remains a leading cause of mortality globally, with death rates exceeding 30%. Current therapies often fall short in addressing its complex pathophysiology, which includes uncontrolled cytokine release, severe oxidative stress, and widespread organ dysfunction. A significant and often debilitating complication is sepsis-related encephalopathy (SAE), characterized by cognitive impairment and neurological deficits. A key challenge in SAE is the disruption of the blood-brain barrier (BBB), allowing inflammatory mediators to damage brain tissue. Developing multi-modal strategies that combine anti-inflammatory, neuroprotective, and antimicrobial actions is crucial to combat this multifaceted disease.

Researchers investigated the therapeutic potential of Buforin IIb and bilirubin co-loaded cerium oxide nanoparticles (designated as CBB NPs) in a cecal ligation and puncture (CLP) mouse model of sepsis. This model mimics human sepsis by inducing polymicrobial infection and systemic inflammation. The study assessed the impact of CBB NPs treatment on 7-day survival rates, systemic inflammatory markers, pathogen burden, and the integrity of the blood-brain barrier (BBB). While specific dosing, route, and frequency were not detailed in the abstract, the primary endpoints focused on overall survival and the amelioration of sepsis-related encephalopathy (SAE), comparing treated groups against untreated septic controls.

Treatment with Buforin IIb and bilirubin co-loaded CeO₂ nanoparticles (CBB NPs) significantly improved outcomes in the CLP sepsis model. The most striking finding was a dramatic increase in survival: > CBB NPs treatment improved 7-day survival from 0% in untreated septic mice to 60%. This robust survival benefit was attributed to the synergistic actions of the loaded compounds. The nanoparticles effectively reduced systemic pro-inflammatory cytokine release, indicating a potent anti-inflammatory effect. Furthermore, CBB NPs demonstrated efficacy in clearing the pathogen burden, addressing the root cause of sepsis. Crucially for neurological outcomes, the treatment ameliorated sepsis-related encephalopathy (SAE) by maintaining blood-brain barrier (BBB) integrity, preventing the influx of damaging inflammatory mediators into the brain. This neuroprotective effect, combined with anti-inflammatory and antimicrobial actions, highlights the multi-target therapeutic potential.